Stock Price & Analysis

The S1 support level for CVKD Stock is $18.15 ,The R1 resistant level for CVKD Stock is $20.46.

As of the end of day on 2025-02-05, the price of CVKD Stock was $18.88.

The target price for CVKD Stock according to analyst rating is 38.50, with the highest price target at 45.00 and the lowest at 32.00. Analysts have a Moderate Buy rating on CVKD Stock overall.

The market cap of CVKD is $35.2M.

Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions. Tecarfarin has orphan drug and fast track designations from the United States Food and Drug Administration for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). It is also pursuing additional regulatory strategies for unmet needs in anticoagulation therapy for patients with left ventricular assist devices (LVADs) and those with thrombotic antiphospholipid syndrome (APS). Tecarfarin is specifically designed to leverage a different metabolism pathway than the commonly prescribed Vitamin K Antagonist (warfarin).

CVKD has a total of 4 employees.